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Summary
Background: Peritumoral clefts are noticed in carcinomas of many organs, and were thought to be artifacts due to 
fi xation and preparation of slides. Today they are considered to be additional marker of malignancy and the refl ection of 
epithelial-stromal interaction. The hypothesis was that peritumoral clefts in breast carcinoma refl ect changes in stromal 
composition and characteristics, and are related to lymphangiogenesis in tumor tissue. Materials and methods: One hun-
derd (59% with axillary lymph nodes metastases) invasive ductal breast carcinomas of no special type were analyzed for the 
presence and abundance of peritumoral clefts and immunohistochemically for CD34, vimentin, smooth muscle actin (SMA) 
and D2-40 (podoplanin) in tumor stroma. Results: Peritumoral clefts were found in 92% of invasive carcinomatous tissue 
and were absent in surrounding healthy tissue and around ducts of in situ component (with 5% do 100%. The threshold of 
30% of peritumoral clefts was determined by receiver operating characteristic (ROC) analysis. The density of small lym-
phatic vessels in the stroma of the tumor, and outside the tumor tissue did not show signifi cant correlation with the thresh-
old value. In patients with axillary metastases, peritumoral lymphovascular invasion (LVI) was found twice and intratu-
moral LVI fi ve times more often than in patients without axillary metastases. Neither peritumoral nor intratumoral LVI were 
signifi cantly correlated with the threshold value of 30%. In patients with axillary lymph node metasases, peritumoral lym-
phovascular invasion (LVI) was found twice as often, and intratumoral LVI 5 times as often than in patients without axillary 
lymph node metastases. Conclusion: Peritumoral clefts in invasive breast carcinoma refl ect stromal changes of fi broblasts 
and are not associated with lymphangiogenesis, that is probably caused by some other pathogenesis. 
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GUSTOĆA LIMFNIH I MALIH KRVNIH ŽILA U STROMI TUMORA I PERITUMORALNOG TKIVA 
U INVAZIVNOM KARCINOMU DOJKE BEZ POSEBNIH OBILJEŽJA
Sažetak
Uvod: Peritumoralne retrakcijske pukotine više se ne smatraju samo artefaktom, već dodatnim pokazateljem ponaša-
nja invazivnih karcinoma mnogih organa. One predstavljaju morfološki odraz promjena u građi i sastavu tumorske strome, 
a možda i jedan od stadija limfangiogeneze tumora. Hipoteza istraživanja bila je da su u tkivu invazivnog duktalnog karci-
noma dojke peritumoralne retrakcijske pukotine povezane s povećanom gustoćom limfnih žila što doprinosi lakšem rasapu 
tumorskih stanica i lošijoj prognozi. Materijal i metode: Analizirano je 100 invazivnih duktalnih karcinoma dojke u žena, 
41% bez, a 59% s metastazama u limfne čvorove aksile. Osim rutinski, analizirana je imunohistokemijska izraženost CD34, 
vimentina, glatkomišićnog aktina (SMA) i CD2-40 (podoplanina). Rezultati: Peritumoralne pukotine su nađene u 92% kar-
cinoma, a u okolnom zdravom tkivu i oko žarišta duktalnog karcinoma in situ nisu nađene. Proširenost pukotina bila je 5% 
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do 100%. Gustoća malih limfnih žila unutar tumora i peritumoralno nije pokazala statistički značajnu povezanost s apsolut-
nim postotkom peritumoralnih pukotina, kao niti s izraženošću peritumoralnih pukotina s obzirom na graničnu vrijednost 
od 30%. U bolesnica s metastazama peritumoralna limfovaskularna invazija (LVI) je nađena 2 puta češće, a intratumoralna 
LVI skoro 5 puta češće nego u bolesnica bez metastaza, što je statistički značajno različito. Ni peritumoralna, niti intratumo-
ralna LVI nisu pokazale statistički značajnu povezanost s apsolutnim postotkom peritumoralnih pukotina, kao niti s izraže-
nošću peritumoralnih pukotina s obzirom na graničnu vrijednost od 30%. Zaključak: U invazivnom duktalnom karcinomu 
dojke peritumoralne pukotine predstavljaju morfološki odraz promijenjenih osobina tumorske strome, ali nisu povezane s 
gustoćom malih krvnih žila kao odrazom limfangiogeneze, čija je patogeneza vjerojatno drugačija.
KLJUČNE RIJEČI: dojka, invazivni duktalni karcinom, limfangiogeneza, angiogeneza
INTRODUCTION
Peritumoral clefts were fi rst described in the 
tissue of prostatic adenocarcinoma, but their im-
portance has long been neglected (1,2). Some stud-
ies resulted in the discovery of an association be-
tween clefting and the more agressive tumor phe-
notype, as well as with shorter periods of 
biochemical relapse of the disease and survival in 
prostatic adenocarcinoma, so the authors pro-
posed that the percentage of peritumoral clefting 
in prostatic adenocarcinoma tissue should be in-
cluded into the diagnostic criteria (5,6). Except in 
prostatic adenocarcinoma, they were also noticed 
in other malignant tumors of the skin, breast, co-
lon, urinary bladder and other organs where they 
are considered to be an additional marker of ma-
lignancy (3-6). The studies of breast carcinomas 
have shown that diﬀ erent degree of peritumoral 
clefts can be observed in about 60% of them, in as-
sociation with the tumor diameter, histological 
type and grade, lymphovascular invasion, axillary 
lymph node metastases, worse prognosis and 
shorter survival. Malignant epithelial tumors are 
characterized by the interaction between the epi-
thelial component and surrounding tumor stroma 
that has an important role in the tumor develop-
ment and progression (7). The amount of peritu-
moral clefts also showed signifi cant statistical cor-
relation with lymphangiogenesis assessed by 
lymph vessel density, and vascular endothelial 
growth factor C (VEGF-C) expression in the center 
and periphery of the tumor (8,9). Some authors 
think that peritumoral clefts represent an unrec-
ognized way of of lymphatic spread through the 
complex network of stromal (pre-lymphatic) 
channels connected to the main lymphatic system 
of the breast, with the stromal retraction that en-
hances the transition od mesenchymal cells into 
endothelial cells, so that peritumoral clefts might 
represent an early, unfi nished stage of lympho-
capillary invasion (8,9). In this study we examined 
intratumoral and peritumoral lymphatic and 
small blood vessel density (LVD and BVD, respec-
tively), tumor cell invasion of lymphatic and small 
blood vessels and their correlation with peritu-
moral clefts. 
MATERIAL AND METHODS
We investigated 100 samples of invasive 
breast carcinoma diagnosed after surgery in the 
period from 1998. to 2007. The tumor tissue was 
retrieved from the archive of Clinical Department 
of Pathology and Cytology ‘Ljudevit Jurak’ of the 
Sestre milosrdnice University Hospital in Zagreb, 
Croatia. Axillary lymph nodes metastases were 
diagnosed in 59% (59/100) of the cases. Besides the 
analysis of the original tumor samples, immuno-
histochemical analysis was done on routinely 
fi xed and paraﬃ  n embedded tissue. The presence 
of fi broblasts and myofi broblasts was assesed us-
ing monoclonal antibodies to vimentin (monoclo-
nal mouse; clone V9; code M 0725; dilution 1:50; 
Dako Epos, Danska), CD34 (monoclonal mouse; 
clone QBEnd 10; code M 7165; dilution 1:50; Dako 
Epos, Danska) and smooth muscle actin –SMA 
(monoclonal mouse; clone 1A4; code M 0851; dilu-
tion 1:50; Dako Epos, Danska) and lymphatic ves-
sels were assessed with D2-40 (monoclonal mouse; 
clone D2-40; code M 3619; dilution 1:100; Dako 
Epos, Danska). Expression of CD34 was also used 
to verify the blood vessels, because the endotheli-
um expresses CD34 antibody. The results were 
visualized by LSAB method on Dako TechMate 
TM automatized system for immunohistochemi-
cal staining using streptavidin immunoperoxi-
dase protocol MSIP. Peritumoral clefts were con-
sidered clear spaces without endothelial lining 
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that separated tumor cells, glands and solid nests 
from the surrounding stroma. Any intensity of en-
dothelial reaction of vascular structures to D2-40 
was considered positive, even if the D2-40 positive 
cells were found only in clusters, without the ob-
vious formation of the lumen. The number of lym-
phatic vessels, lymphovascular density (LVD) and 
the number of small blood vessels, blood vessel 
density (BVD) was determined in the ‘hot spot’ 
area inside the tumor tissue (intratumoral) and in 
the surrounding tissue (peritumoral). Intratumor-
al lymphatic and blood vessels were considered 
those localized in the stroma, between tumor cell 
nests, while peritumoral lymphatic channels were 
considered those localized in the narrow area of 
the normal breast tissue, up to 2 mm outside the 
tumor tissue. In order to determine ‘hot spot’ ar-
eas with greatest LVD and BVD, tissue samples 
were examined under the 40x magnifi cation. The 
density of vessels was assessed by counting them 
at 5 high power fi elds at 400x magnifi cation, and 
noted as the absolute number. Lymphovascular 
invasion (LVI) was defi ned as the fi ndings of at 
least one tumor cell cluster inside the vascular 
channel showing undoubted both D2-40 and 
CD34 positivity. Vascular invasion (BVI)was de-
fi ned as the fi ndings of at least one tumor cell clus-
ter inside the vascular channel showing only CD34 
positivity. LVI and BVI was assessed on the whole 
surface of the tumor tissue, on slides at 40x magni-
fi cation and noted as the absolute number of lym-
phocapillary and small blood vessel invasive foci 
inside the tumor and in the peritumoral area. Af-
ter the assessment of peritumoral clefts, ROC (re-
ceiver operating characteristic) curve was calcu-
lated, dividing the patients into two prognostical-
ly diﬀ erent groups (those with and without 
metastases) and determined the predictive, cut-oﬀ  
value for the percentage of peritumoral clefts, 
which was 30%. According to the cut-oﬀ  value the 
patients were grouped in 2 groups: 1 – with peri-
tumoral clefts in ≤ 30% of the tumor surface, and 2 
– with peritumoral clefts in > 30% of tumor surface 
(the latt er was considered to be extensive fi nd-
ings). Except for intratumoral and peritumoral 
LVD and LVI, histopathological chacteristics com-
pared with peritumoral clefts were patt ern of 
growth (expansive vs. infi ltrative), tumor diame-
ter in milimeters, pT stage, histological grade (ac-
cording to Elston and Ellis modifi cation of Not-
tingham classifi cation) (10), axillary lymph node 
status (pN stage), the ratio of positive and nega-
tive lymph nodes, hormone receptor and HER2/
neu status assesed by immunohistochemistry, and 
the age of the patients. For statistical analysis 
Spearman coeﬃ  cient of correlation, Mann-Whit-
ney U test and Wilcoxon tests were used. For the 
analysis of categories of variables c2 test was used. 
ROC analysis was used for determination of sta-
tistically signifi cant cut oﬀ  value of the percentage 
of peritumoral clefts. All p values < 0,05 were con-
sidered signifi cant. Program support IBM SPSS 
statistics 19.0.0.1 was used. 
RESULTS
Peritumoral clefts were found in 92% (92/100) 
of invasive ductal carcinoma of no special type, in 
the range from 5% to 100%. In patients whose tu-
mors showed extensive peritumoral clefts signifi -
cant correlation with larger diameter of the tumor 
(p=0.009), pT stage of disease (p=0.018), presence 
of metastases in axillary lymph nodes (p<0.001) 
and the ratio of positive vs. negative lymph nodes 
(p<0.001), but the age of the patients, hormonal 
status, tumor grade, LVD in the tumor and the 
peritumoral area, lymphovascular and vascular 
invasion in the tumor and in the peritumoral area 
did not show correlation with the expression of 
peritumoral clefts. Immunohistochemical reaction 
to D2-40, showed intratumoral lymphatic vessels 
in 56% (56/100) of carcinomas, while 100% of car-
cinomas contained peritumoral lymphatic vessels. 
Intratumoral lymphatic vessels were small, linear 
and narrow, while peritumoral lymphatic vessels 
showed larger diameter and wider lumen (Figure 
1). Median number of intratumoral lymphatic ves-
sels was 2.5 vessels/5 high power fi leds (HPF). 
Median number of peritumoral lymphatic vessels 
was 15 vessels/5HPF (Wilcoxon test, p<0,001) (Ta-
ble 1). No signifi cant diﬀ erences were found when 
medians of LVD and small BVD were compared 
between the group of tumors containing smaller 
and larger number of myofi broblasts, respectively 
(Table 2). Lymphovascular invasion (LVI) was 
found inside the tumor tissue in 13% (13/100) of 
the cases, while peritumoral LVI was found in 43% 
(43/100) of the cases (Wilcoxon test, p<0.001). In 
the tumor stroma the number of lymphatic vessels 
containing tumor thrombi ranged from 1 to 30, 
and outside the tumor the number of vessels con-
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taining tumor thrombi ranged from 1 to 37 (Figure 
2). (Wilcoxon test, p<0.001). Out of 13 patients 
with intratumoral LVI, 11 had metastases in axil-
lary lymph nodes. Out of 43 patients with peritu-
moral LVI, 32 had metastases in axillary lymph 
nodes. In 41 patients axillary metastases intratu-
moral LVI was found in 4% (2/41), and peritumor-
al in 27% (11/41). In 59 patients with axillary me-
tastases intratumoral LVI was found in 19% 
(11/59), and peritumoral in 54% (32/59) of breast 
carcinomas (p<0.001).
Small blood vessels highlighted by CD34 ex-
pression were found both in the intra and peritu-
moral stroma in all 100 cases (100%) (Figure 3). 
The median of the number of small blood vessels 
was 89 vessels/5HPF, and in the peritumoral area, 
median of BVD was 38.5 vessels/5HPF (Wilcoxon 
test, p<0.001) (Table 3). Vascular invasion was 
found in only 1/100 cases in the tumor tissue, and 
in 3/100 cases in the peritumoral area. In tumors 
Table 1. 
NUMBER OF SMALL INTRATUMORAL AND PERITUMORAL LYMPHATIC VESSELS IN 100 INVASIVE DUCTAL BREAST 
CARCINOMAS OF NO SPECIAL TYPE 
Quantitative parameter N Min Max
Percentile
25. Median 75.
Intratumoral small lymphatic vessel density (on 5 HPF) 100 0.00 31.00 0,00 2.50 8.00
Peritumoral small lymphatic vessel density (on 5 HPF) 100 3.00 38.00 9,00 15.00* 2000
*Wilcoxon test, p<0.001
Figure 1. Intratumoral lymphatic vessels are mostly small and 
narrow (bott om left, D2-40 x 200), while peritumoral lymphatic 
vessels show larger diameter and widely opened lumen (bott om 
right, D2-40 x 200).
Figure 2. Lymphovascular invasion (tumor thrombi). White ar-
rows point towards the tumor thrombus inside the lymphatic ves-
sels that show positivity for CD34 and D2-40. Left intratumoral; 
right peritumoral (from top to bott om: HE, CD34, D2-40) 
Figure 3. Comparison of two ‘hot spots’ in invasive ductal breast 
carcinoma, left with higher CD34 positive blood vessel density, 
and right with lower CD34 positive blood vessel density. 
9Lib Oncol. 2018;46(1):5–13
with expansile patt ern of growth (39%) median 
number of intratumoral lymphatic vessels vas 
found to be 1/5 HPF, while in tumors with infi ltra-
tive patt ern of growth (61%) this number was 
4/5HPF (p<0,001). 
DISCUSSION
The increase of small blood vessel density 
due to neoangiogenesis in breast carcinoma tissue 
is clearly related to the development of distant 
metastases (11-13). So far the studies have not 
shown the correlation of neoangiogenesis with re-
gional lymph node metastases, and lymphatic 
vessels are still considered to be the primary way 
of carcinoma cells spreading into the regional 
lymph nodes (11-13). 
Until approximately a decade ago, there were 
no reliable markers to diﬀ erentiate between small 
blood and small lymphatic vessels, resulting in 
relatively small number of studies of lymphangio-
genesis. The discovery od specifi c lymph vessel 
marker such as D2-40 (podoplanin) facilitated the 
diﬀ erentiation between small lymphatic and small 
blood vessels (14,15). Earlier studies showed that 
the intratumoral BVD is a reliable sign of tumor 
induced angiogenesis, so it was expected that the 
quantitative analysis of intratumoral and peritu-
moral LVD in comparison to LVD in the healthy 
breast tissue might shed some light on the ques-
tions about lymphangiogenesis in breast carcino-
Table 2. 
DENSITY OF INTRATUMORAL AND PERITUMORAL SMALL LYMPHATIC AND BLOOD VESSELS, AND LYMPHOVASCULAR AND 
VASCULAR INVASION IN RELATION TO THE INTENSITY OF SMA EXPRESSION IN THE STROMA OF 100 INVASIVE DUCTAL 
BREAST CARCINOMAS OF NO SPECIAL TYPE (N.S.) 
Quantitative parameter Intesity of stromal SMA expression N Min Max
Percentile
25. Median 75.
Intratumoral small lymph vessel density 
(on 5 HPF)
Weak 43 0 31 0.00 2.00 7.00
Strong 57 0 22 0.00 3.00 8.00
Peritumoral small lymph vessel density (on 5 HPF)
Weak 43 3 38 9.00 17.00 21.00
Strong 57 3 28 10.50 15.00 20.00
Intratumoral lymphovascular invasion 
Weak 43 0 30 0.00 0.00 0.00
Strong 57 0 3 0.00 0.00 0.00
Peritumoral lymphovascular invasion
Weak 43 0 20 0.00 0.00 1.00
Strong 57 0 37 0.00 0.00 2.00
Intratumoral small blood vessel density (on 5 HPF)
Weak 43 32 239 56.00 84.00 109.00
Strong 57 34 208 61.50 92.00 127.00
Peritumoral small blood vessel density (on 5 HPF)
Weak 43 15 107 27.00 35.00 47.00
Strong 57 14 86 31.50 41.00 52.00
Intratumoral vascular invasion
Weak 43 0 1 0.00 0.00 0.00
Strong 57 0 0 0.00 0.00 0.00
Peritumoral vascular invasion
Weak 43 0 5 0.00 0.00 0.00
Strong 57 0 1 0.00 0.00 0.00
Table 3. 
THE NUMBER OF SMALL INTRATUMORAL AND PERITUMORAL BLOOD VESSELS IN 100 INVASIVE DUCTAL BREAST 
CARCINOMAS OF NO SPECIAL TYPE.
Quantitative parameter N Min Max
Percentile
25. Median 75.
Intratumoral small blood vessel density (on 5 HPF) 100 32.00 239.00 60.00 89.00* 122.50
Peritumoral small blood vessel density (on 5 HPF) 100 14.00 107.00 29.25 38.50 49.75
* Wilcoxon test p>0.001
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ma (15). However, the results of the studies are 
diﬀ erent. Agarwal and co. used D2-40 to study the 
density of intra and peritumoral lymphatic vessels 
and described signifi cantly smaller intra and peri-
tumoral LVD in breast carcinoma than in the 
healthy breast tissue, benign breast lesions and 
carcinoma in situ (16). Other authors described 
that the intratumoral LVD determined by D2-40 
did not diﬀ er signifi cantly from the density in the 
healthy breast tissue (17). Several authors noticed 
lymphatic vessels only in the vicinity of the preex-
isting ducts and lobules, and thought that they 
were the remains of normal lymphatic vessels en-
trapped within the tumor tissue (16, 17). Because 
the majority of small blood vessels within the tu-
mor were not accompanied by lymphatic vessels, 
it was accepted that the invasion by tumor cells 
destroys lymphatic vessels and that the peritu-
moral blood vessels suﬃ  ce for the development of 
lymphogenous metastases (18). More recent stud-
ies are more in favor of the process of lymphangi-
ogenesis, describing the possible mechanism of its 
development (19-21). 
Lymphangiogenic factors, secreted by malig-
nant epithelial, but also stromal cells, like vascular 
endothelial growth factor-C (VEGF-C) and vascu-
lar endothelial growth factor D (VEGF-D) were 
discovered (22-24). The pathogenesis of their ac-
tion is thought to be the activation of vascular en-
dothelial growth factor receptor-3 (VEGFR-3) 
(22,23). Some tried to resolve the question of active 
formation of new lymphatic vessels by double im-
munohistochemical staining for D2-40 and prolif-
eration marker Ki-67, again with the conclusion 
that there is no lymphangiogenesis in breast carci-
noma tissue (16). The use of D2-40 enabled some 
authors to visualize intratumoral lymphatic ves-
sels in 80 to 85% of carcinomas, while van der 
Schaft and co. found them in only 12 % of carcino-
mas (25-26). The diﬀ erences between the number 
of lymphatic vessels that were found in diﬀ erent 
studies might be explained by the diﬀ erent meth-
odologies of counting, like diﬀ erent locations 
where they were counted within the tumor tissue 
and diﬀ erent magnifi cations at counting. In this 
study the endothelium of lymphatic vessels was 
also visualised with D2-40 antibody (podoplanin) 
and they were found in intratumoral stroma in 
56% of invasive ductal breast carcinomas. Intratu-
moral lymphatic vessels were mostly small and 
linear with the narrow lumen. They appeared to 
be squeezed from the outside by the malignant 
epithelial cells, and on the routinely H-E stained 
sections they were inconspicuous. The median of 
intratumoral lymphatic vessels in this study was 
2,5 vessels/5HPF, while in some other studies the 
range was very wide: from 0,3 to 9,7 (16,17,26). In 
spite of the diagnostic value and usefullness of 
D2-40 as a lymphatic vessel marker, the identifi ca-
tion of the relatively small number of intratumoral 
lymphatic vessels is not easy and their distribu-
tion within the tumor tissue is heterogeneous, so 
many of them might not be present at the very 
slide containing the sample of tumor tissue used 
for immunohistochemical analysis. Van der Au-
wera and co. stress that the intratumoral LVD de-
pends upon the tumor patt ern of growth, because 
they found less lymphatic vessels in carcinomas 
showing expansile patt ern of growth than in carci-
noma with infi ltrative patt ern of growth. Carcino-
mas with expansile growth are relatively well cir-
cumscribed, made of malignant epithelial cell and 
desmoplastic tumor stroma and do not contain 
normal breast tissue within the tumor mass, while 
in carcinomas with infi ltrative growth rows of tu-
mor cells infi ltrate between the preexisting breast 
structures that contain also the lymphatic vessels. 
In their opinion, the fi ndings of lymphatic vessels 
in carcinomas with expansile patt ern confi rm 
strongly the process of intratumoral lymphangio-
genesis (27). The results of this study are similar to 
the results of the study by Van der Auera and co. 
with the median of intratumoral LVD in carcino-
mas with expansile growth being signifi cantly 
higher than in carcinomas with infi ltrative growth 
patt ern (27). This diﬀ erence is in favor of the opin-
ion that breast carcinomas contain intratumoral 
lymphatic vessels that are more numerous in tu-
mors showing infi ltrative patt ern of growth, but 
can also be found in tumors with expansile 
growth, in the desmoplastic stroma that shows 
diﬀ erent phenotypic characteristics than the nor-
mal breast stroma. 
According to some studies intratumoral LVD 
is not correlated with the diameter and grade of 
the carcinoma, nor with the lymph node status, 
but other studies have found their correlation 
with lymphovascular invasion and metastases to 
axillary lymph nodes, carcinoma diameter, grade 
and stage of the disease (17,18). The results of this 
study show that intratumoral lymphatic vessels 
are present in some breast carcinomas, but be-
11
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cause of their appearence, small number that de-
pends upon the patt ern of tumor growth and un-
certain correlation with clinical parameters, their 
role in the development of regional lymph node 
metastases is not clear. 
In this study, lymphatic vessels were found 
in the peritumoral tissue in all 100 cases of breast 
carcinoma. They were large, with widely opened 
lumens, and could be easily found on routinely 
stained slides. This fi nding confi rms fi ndings of 
other studies (17,26). The median of their density 
was signifi cantly higher than inside the tumor 
stroma and some of them contained tumor embo-
li, similar to the fi ndings of other authors (17, 18, 
28). Although the opinions about the prognostic 
signifi cance of intratumoral LVD diﬀ er, there 
seems to be an agreement about the role of peritu-
moral lymphatic vessels that might be suﬃ  cient 
for the tumor cells to reach the regional lymph 
nodes even in the absence of intratumoral lym-
phatic vessels (17-19,28,29). There is no straight-
forward answer to the question whether peritu-
moral lymphatic vessels are preexistant or are 
newly formed. The results of the studies that in-
cluded the expression of proliferation markers are 
in favor of the active lymphangiogenesis, but it 
seems that some tumors still do not succeed in in-
duction of new lymphatic vessels at their periph-
ery (30-33). 
Whether in preexistant or newly formed lym-
phatic vessels, lymphovascular invasion is defi ned 
as the presence of the tumor thrombus inside the 
vascular space lined by endothelium (34). In the 
routine H-E stained sections, LVI can easily be 
mistaken for a cluster of epithelial cells surround-
ed by a peripheral retraction cleft, and blood ves-
sel is sometimes diﬃ  cult to diﬀ erentiate from the 
lymphatic vessel, so the main characteristic for 
their diﬀ erentiation is the erythrocyte content in 
the blood vessels. Tumor thrombus can also com-
pletely fi ll the vessel lumen, making it diﬃ  cult to 
discern it from the surrounding tumor cells, so 
LVI is lately also asessed immunohistochemically 
with D2-40. In their stuy, De Mascarel and co. 
compared the location and number of tumor 
thrombi in carcinomas without axillary lymph 
node metastases in tumor sections stained by H-E 
and D2-40. In sections stained by H-E tumor 
thrombi were found in 15% of carcinomas, away 
from the main tumor mass, while in the tissue 
stained by D2-40 they were found in 41%, they 
were multiple, widespread and localized nearer to 
the main tumor mass (34). In their study, only the 
presence of peritumoral thrombi had prognostic 
signifi cance, the same as in other studies that 
showed the signifi cant correlation of peritumoral 
LVI with lymph node metastases (34-36). In this 
study, peritumoral LVI was found twice as often 
in patients who had lymph node metastases than 
in the patients who had not, similar to the results 
from the literature, and stressing the importance 
of peritumoral LVI in tumor spreading. Intratu-
moral LVI was found in 4% of the tumors without 
lymph node metastases and in 19% of the tumors 
that spread to the lymph nodes, which is signifi -
cant. These fi ndings point out to the importance 
LVI fi ndings with regard to the possibility of 
lymph node metastases and, accordingly, in-
creased risk of recurrence and shorter survival. 
This fi nding can have a role in screening of the pa-
tients with negative axillary lymph nodes, who 
might benefi t from adjuvant chemotherapy. 
Pathophysiology of blood vessels is entirely 
diﬀ erent. Because blood vessels provide tumor tis-
sue with oxygen and nutrients, they are associated 
with growth promotion and hematogenous 
spread. Japanese authors showed that small BVD 
is the independent determinant of the duration of 
remission and total survival (12, 37, 38). Meta anal-
ysis of 43 independent studies showed signifi cant 
correlation of high density of small blood vessels 
with shorter survival in breast carcinoma patients, 
especially those with negative lymph nodes (12). 
As with counting of the lymphatic vessels, diﬀ er-
ent results of the studies refl ect diﬃ  culties and dif-
ferences in counting of small blood vessels, but 
most authors agree that angiogenesis in breast car-
cinoma exists. El-Gendi and co. found the median 
number of small blood vessels in the tumor tissue 
to be 17.9 vessels/1 HPF (29). The results of this 
study are similar, with median number of small 
blood vessels in “hot spot” being 8 vessels/5 HPF. 
When compared with signifi cantly smaller BVD in 
the peritumoral area that was 38.5/5HPF, this fi nd-
ing is an obvious sign of angiogenesis. The results 
by El-Gendi and co. do not show the signifi cant 
correlation od BVD with carcinoma diameter and 
grade, LVI and lymph node metastases, but they 
showed signifi cant correlation of BVD inside the 
tumor with LVD, suggesting the common devel-
opmental pathway for both angiogenesis and lym-
phangiogenesis (29). Although small BVD is cer-
Lib Oncol. 2018;46(1):5–13
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tainly important for tumor cells survival, the clini-
cal implications of aforementioned fi ndings 
remain uncertain. As opposed to LVI, BVI with 
tumor cells is rarely found. In one of the earliest 
and largest studies of this feature, tumor invasion 
into the blood vessels was found in 4,2% while a 
more recent study reported blood vessel invasion 
in 1.1% of the cases (38,39). In this study, intratu-
moral blood vessel invasion was found in only 
1/100 cases, and peritumoral blood vessel invasion 
was found in 3/100 cases. In some studies, both 
LVI and BVI are considered a bad prognostic fea-
ture, but the majority of studies showed only the 
correlation of LVI with shorter survival (14, 28, 36, 
39,40). Acs and co. found the signifi cant correla-
tion of the presence of extensive peritumoral clefts 
with lymphangiogenesis, as measured by LVD 
and VEGF-C expression. (9, 41). In this study peri-
tumoral clefts were found in 92% of tumors, with 
immunohistochemically proven changes of stro-
mal cells phenotype. These changes are in accor-
dance with the role of CAFs in tumor spread and 
their role in tumor stroma infi ltration and metasta-
sis. As far as is known today, this role seems to be 
one of the most important for tumor agressiveness 
(41-43). Therefore, it seems plausible that the 
growth factors as well as others, still not complely 
understood soluble mediators produced and ex-
creted by CAFs may have a role in both angio and 
lymphangiogenesis in breast carcinoma. 
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